Locally Advanced Breast Cancer during the COVID-19 Pandemic
Keywords:
locally advanced breast cancer, clinical stage, surgical treatment, pandemic, mastectomyAbstract
Introduction: The epidemiological situation caused by COVID-19 had implications for cancer care, service provision, mortality, and the economic impact on health systems.
Objective: To determine the behavior of patients with locally advanced breast cancer during the COVID-19 pandemic.
Methods: A descriptive retrospective longitudinal study was conducted at the Calixto García University General Hospital (April 2020 to April 2022). The sample consisted of 55 patients diagnosed with locally advanced breast cancer who met the selection criteria. Theoretical and empirical methods were used, accompanied by a set of logical thought processes: analysis, synthesis, abstraction, generalization, among others.
Results: In 67% of the patients studied, it was necessary to start neoadjuvant treatment, and in the remaining 33%, surgery could be started. The predominant age groups were 60-69 and 70-79, and the predominant histological variety was invasive ductal carcinoma, while the surgical alternatives for treatment were modified radical mastectomy and simple mastectomy.
Conclusions: Invasive ductal carcinoma was the most common histological type, and modified radical mastectomy was the most frequently used surgical treatment.
Downloads
References
1. Sharpless NE. COVID‐19 and cancer. Science. [acceso 23/05/2024];368 (6497):1290. Disponible en: https://pubmed.ncbi.nlm.nih.gov/32554570/
2. Dinmohamed AG, Visser O, Rob HA. Verhoeven WJ Louwrnan H, van Nederveen E, et. al. Fewer cancer diagnoses during the COVID-19 epidemic in the Netherlands. Lancet Oncol. 2020 [acceso 23/05/2024];21(6):750‐1. Disponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7252180/
3. Kutikov A, Weinberg DS, Edelman MJ, Horwitz EM, Uzzo RG, Fisher RI. A War on Two Fronts: Cancer Care in the Time of COVID-19. Ann Intern Med. 2020 [acceso 23/05/2024];172(11):756-8 Disponible en: https://www.ncbi.nlm.nih.gov/ pmc/articles/PMC7133056/pdf/aim-olf-M2011 33.pdf
4. Maringe C, Spicer J, Morris M, Purushotham A, Nolte E, Sullivan R, Rachet B, et al. The impact of the COVID-19 pandemic on cancer deaths due to delays in diagnosis in England, UK: a national, population-based, modelling study. Lancet Oncol. 2020 [acceso 23/05/2024];21(8):1023‐34. Disponible en: https://www.ncbi.nlm. nih.gov/pmc/articles/PMC7417808/
5. National Cancer Institute’s PROSPR Consortium. Corley DA, Sedki M, Ritzwoller DP, Greenlee RT, Neslund C, et. al. Cancer Screening During the Coronavirus Disease-2019 Pandemic: A Perspective from the National Cancer Institute's PROSPR Consortium. J Gast. 2020 [acceso 23/05/2024]; 160(4): 999-1002. Disponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7575503/
6. World Health Organization (WHO). Cancer. 2022. [acceso 23/05/2024] Disponible en: https://www.who.int/news-room/fact-sheets/detail/cancer
7. Hyuna Sung, Ferlay J, Siegel R, Laversanne M, Soerjomataram I, Jemal A, Bray F. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clín. 2021 [acceso 23/03/2024]; 71(3): 209-249. Disponible en: https://acsjournals.online library.wiley.com/doi/epdf/10.3322/caac.21660
8. Ferlay J, Oolombert M, Soerjomataram DM, Pineros M, Znaor A, Bray F. Cancer statistics for the year 2020: An overview. Int J Cancer. 2020 [acceso 23/02/2024] Disponible en: https://pubmed.ncbi.nlm.nih.gov/33818764/
9. Organización Mundial de la Salud. (OMS). Cáncer. 2018. [acceso 23/03/2024]; Disponible en: https://www.who.int/es/news-room/fact-sheets/detail/cancer
10. United Nations Development Programmer (UNDP). Human Development Report 2019. Beyond Income, Beyond Averages, Beyond Today: Inequalities in Human Development in the 21st Century. UNDP; 2019 [acceso 23/02/2024]. Disponible en: https://reliefweb.int/attachments/27997facd150394bbda1a668a7045473/hdr2019.pdf
11. Ngan TT, Nguyen NTQ, Van Minh H, Donnelly M, O'Neill C. Eficacia del examen clínico de mamas como modalidad de cribado «independiente»: una visión general de las revisiones sistemáticas. Cáncer BMC. 2020 [acceso 23/02/2024]; 20:1070. Disponible en: https://pure.qub.ac.uk/en/publications/effectiveness-of-clinical-breast-examination-as-a-stand-alone-scr
12. Birnbaum JK, Duggan C, Anderson BO, Etzioni R. Early detection and treatment strategies for breast cancer in lowing come and upper middle-income countries: a modelling study. Lancet Glob Health. 2018 [acceso 23/02/2024];6:e885‐93. Disponible en: https://pubmed.ncbi.nlm.nih.gov/30012269/
13. Torre LA, Islami F, Siegel RL, Ward EM, Jemal A. Global Cancer in Women: Burden and Trends. Cancer Epid Biomarkers Prev. 2017 [acceso 02/02/2024];26(4):444-57. Disponible en: https://pubmed.ncbi.nlm.nih.gov/28223433/
14. Rodríguez Y, Díaz MT, Rodríguez R. Cáncer y COVID-19, un vínculo peligroso. Gac Méd Espirit. 2022 [acceso 02/02/2024]; 24(3). Disponible en: http://scielo.sld.cu/ scielo.php?script=sci_arttext&pid=S1608-89212022000300011&lng=es
15. Cachaperín L. Diagnóstico del cáncer de mama durante la pandemia por covid-19. Una revisión sistemática. [trabajo de fin de grado en Enfermería]. España: Univ de Valladolid. España; 2022. [acceso 04/03/2024] Disponible en: https://uvadoc .uva.es/bitstream/handle/10324/54162/TFG-H2465.pdf?sequence=1
16. Marquina A, Comín L. ¿Ha influido la pandemia por COVID-19 en el diagnóstico del cáncer de mama? J Sen Breast Dis. 2023; 36(3). DOI: https://doi.org//10.1016/j.senol.2023.100472
17. Maringe C, Spicer J, Morris M, Purushotham A, Nolte R, Aggarwal A. The impact of the COVID-19 pandemic on cancer deaths due to delays in diagnosis in England, UK: a national, population-based, modelling study. Lancet Onc. 2020 [acceso 2/04/2024]; 21(8):1023-34. Disponible en: https://www.sciencedirect.com/science /article/pii/S1470204520303880
18. Castañeda C, Castro FJ, Verano NC. Pandemia Covid-19: impacto y desafíos sanitarios y sociales. Univ Soc. 2021 [acceso 2/04/2024];13(S3):8–17. Disponible en: https://rus.ucf.edu.cu/index.php/rus/article/view/2443
19. Pérez K. Cáncer de mama IIa, Iib y IIIa operadas con ganglios positivos. Centro Nacional Coordinador de Ensayos Clínicos. (CENCEC). Cuba. Report No. RPCEC 00000070. 4 Abr 2014. [acceso 2/04/2024]; Disponible en: http://www.rpcec.sld.cu/ ensayos/RPCEC00000070-Sp/
20. Centro de Inmunología Molecular (CIM). Vacuna NGcGM3/VSSP/Montanide ISA 51 en cáncer de mama IIa, Iib y IIIa operadas con ganglios positivos y libres de enfermedad. Fase IIb/III. IIC. Registro Público Cubano de Ensayos Clínicos. RD-EC083. 4 Jun 2018. [acceso 2/04/2024]; Disponible en: https://rpcec .sld.cu/ensayos/RPCEC00000070-Sp
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2026 http://creativecommons.org/licenses/by-sa/4.0
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
La Revista Cubana de Cirugía forma parte de la biblioteca SciELO, que comprende la publicación en línea de colecciones nacionales de revistas. Se adopta la licencia Creative Commons (CC), internacionalmente adoptada por las colecciones de revistas científicas de acceso abierto.
La Licencia de Atribución No Comercial 4.0 Unported, elegida para las colecciones de SciELO, permite a los usuarios acceder, exhibir públicamente la obra, así como crear obras derivadas con la condición de darle crédito al autor, tal como se especifica en la revista. A través de esta licencia queda explícita la restricción del uso comercial de los contenidos.
